SeekingAlpha · Dec 29, 2025
Cidara: Merck's Acquisition Based On CD388 Flu Prevention Potential
Cidara Therapeutics skyrockets 1,165% after positive CD388 data and Merck's acquisition bid. Read why CDTX stock is a Hold.
CD
NASDAQ · CDTX
Cidara Therapeutics, Inc.
Healthcare · Biotechnology
$221.38
Up+$0.00 (+0.00%)
Updated Aug 13, 2026, 9:47 PM
SID Score
5.4/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 5.58B
- P/E ratio
- -32.03
- Dividend yield
- 0.00%
- 52-week range
- $18.38 – $221.42
- Volume
- 2.69M
- Avg. volume
- 1.45M
Price performance
CDTX price history
1M range · 0 trading sessions · Daily adjusted prices
CDTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest CDTX news
The latest Smart Investors Daily articles mentioning CDTX.
Stock researchCompany · Overview
CDTX research
Overview
Company profile and research snapshot.
Company profile
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $177.88
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 18, 2025 | Guggenheim | Neutral | — |
| Nov 14, 2025 | HC Wainwright & Co. | Neutral | — |
| Nov 14, 2025 | Needham | Hold | — |
| Nov 7, 2025 | RBC Capital | Outperform | — |
| Nov 7, 2025 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
The Motley Fool · Dec 9, 2025
Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump
Merck's stock rose after positive clinical trial results for Winrevair, a pulmonary hypertension drug acquired through the Acceleron Pharmaceuticals acquisition. The company is strategically preparing for the Keytruda patent expiration in 2028 by developing new drugs and potential treatment expansions.
The Motley Fool · Dec 7, 2025
Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
Merck's stock has experienced significant volatility, dropping from $130 to $76 and rebounding to around $100. Despite concerns about Keytruda's patent expiration in 2028, the company shows potential through new drug developments, acquisitions, and a promising pharmaceutical pipeline.
defenseworld.net · Dec 1, 2025
Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX
Geode Capital Management LLC grew its position in shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) by 576.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 372,010 shares of the biotechnology company's stock after buying an additional 317,027 shares during the period.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
